Click on a filter below to refine your search. Remove a filter to broaden your search.
Proportionately lower log odds were seen for heart disease, heart attack, stroke and composite outcome for days of use between zero and 30 a month.
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.